Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients

Kidney International

Volumn 57, Issue 1, 2000, Pages 282-292

  Indridason, O S ^a   Quarles, L D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adynamic bone disease; Alkaline phosphatase; Calcitriol; Calcium; Dialysis; Parathyroid hormone; Phosphorus; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM;

EID: 0034049012     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00819.x     Document Type: Article

References (39)

1. M.M. Salem Hyperparathyroidism in the hemodialysis population: A survey of 612 patients Am J Kidney Dis 29 1997 862 865
2. S.G. Massry J.W. Coburn D.B. Lee J. Jowsey C.R. Kleeman Skeletal resistance to parathyroid hormone in renal failure: Studies in 105 human subjects Ann Intern Med 78 1973 357 364
3. L.D. Quarles B. Lobaugh G. Murphy Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia J Clin Endocrinol Metab 75 1992 145 150
4. Q. Qi M.C. Monier-Faugere Z. Geng H.H. Malluche Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis Am J Kidney Dis 26 1995 622 631
5. I.B. Salusky J.A. Ramirez W. Oppenheim B. Gales G.V. Segre W.G. Goodman Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD Kidney Int 45 1994 253 258
6. M. Wang G. Hercz D.J. Sherrard N.A. Maloney G.V. Segre PEI: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity Am J Kidney Dis 26 1995 836 844
7. L.D. Quarles D.A. Yohay B.A. Carroll C.E. Spritzer S.A. Minda D. Bartholomay B.A. Lobaugh Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD Kidney Int 45 1994 1710 1721
8. W.G. Goodman J.A. Ramirez T.R. Belin Y. Chon B. Gales G.V. Segre I.B. Salusky Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy Kidney Int 46 1994 1160 1166
9. 3 inhibits parathyroid cell proliferation in experimental uremia Kidney Int 35 1989 1049 1056
10. 3 in experimental renal hyperparathyroidism Kidney Int 44 1993 1259 1265
11. E. Slatopolsky C. Weerts K. Norwood K. Giles P. Fryer J. Finch D. Windus J. Delmez Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism Kidney Int 36 1989 897 903
12. M. Rudnicki J. Hojsted L.J. Petersen H.A. Sorensen L. Hyldstrup I. Transbol Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: A randomized double-blind placebo-controlled study Nephron 65 1993 369 374
13. L.D. Quarles G.A. Davidai S.J. Schwab D.W. Bartholomay B. Lobaugh Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism Kidney Int 34 1988 840 844
14. K. Schaefer E. Umlauf D. Von Herrath Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night Am J Kidney Dis 19 1992 460 464
15. R.H. Christenson Biochemical markers of bone metabolism: An overview Clin Biochem 30 1997 573 593 10.1016/s0009-9120(97)00113-6
16. P. Urena M. Hruby A. Ferreira K.S. Ang M.C. De Vernejoul Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients J Am Soc Nephrol 7 1996 506 512
17. M.M. Couttenye P.C. D'haese V.O. Van Hoof E. Lemoniatou W. Goodman G.A. Verpooten M.E. De Broe Low serum levels of alkaline phosphatase of bone origin: A good marker of adynamic bone disease in haemodialysis patients Nephrol Dial Transplant 11 1996 1065 1072
18. D.A. Jenkins D. Gouldesbrough G.D. Smith J.F. Cowie R.J. Winney Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity? Nephrol Dial Transplant 4 1989 51 56
19. H.H. Liou S.S. Chiang T.P. Huang S.D. Shieh M. Akmal Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients Miner Electrolyte Metab 20 1994 97 102
20. E.R. Fischer D.C. Harris Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism Clin Nephrol 40 1993 216 220
21. O.S. Indridason L.D. Quarles Oral versus intravenous calcitriol: Is the route of administration really important? (review) Curr Opin Nephrol Hypertens 4 1995 307 312
22. P.K. Nielsen U. Feldt-Rasmussen K. Olgaard A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells Nephrol Dial Transplant 11 1996 1762 1768
23. T. Naveh-Many R. Rahamimov N. Livni J. Silver Parathyroid cell proliferation in normal and chronic renal failure rats: The effects of calcium, phosphate, and vitamin D J Clin Invest 96 1995 1786 1793
24. M. Rodriguez A. Martin-Malo M.E. Martinez A. Torres A.J. Felsenfeld F. Llach Calcemic response to parathyroid hormone in renal failure: Role of phosphorus and its effect on calcitriol Kidney Int 40 1991 1055 1062
25. I.B. Salusky W. Goodman Skeletal response to intermittent calcitriol therapy in secondary hyperparathyroidism Kidney Int 53 Suppl 1996 S135 S139
26. G. Coen P. Ballanti E. Bonucci S. Calabria M. Centorrino V. Fassino M. Manni D. Mantella S. Mazzaferro I. Napoletano D. Sardella F. Taggi Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients Nephrol Dial Transplant 13 1998 2294 2302
27. P. Urena P. Prieur M. Petrover Alkaline phosphatase of bone origin in hemodialyzed patients: 110 assays Presse Med 25 1996 1320 1325
28. O.S. Indridason L.D. Quarles Prevention and management of renal osteodystrophy in dialysis patients, Renal Osteodystrophy edited by Bushinski DA 1997 Lippincott-Raven Philadelphia 445 472
29. D.J. Sherrard D.L. Andress Aluminum-related osteodystrophy Adv Intern Med 34 1989 307 323
30. L.D. Quarles H.J. Gitelman M.K. Drezner Aluminum: Culprit or accessory in the genesis of renal osteodystrophy Semin Nephrol 6 1986 90 101
31. R.F. Spurney P. Min P. Flannery L.D. Quarles Aluminum is a weak agonist for the calcium-sensing receptor Kidney Int 55 1999 1750 1758
32. I.B. Salusky J. Foley P. Nelson W.G. Goodman Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease N Engl J Med 324 1991 527 531
33. W.F. Pinggera M.M. Popovtzer Uremic osteodystrophy: The therapeutic consequences of effective control of serum phosphorus JAMA 222 1972 1640 1642
34. G.A. Block T.E. Hulbert-Shearon N.W. Levin F.K. Port Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study Am J Kidney Dis 31 1998 607 617
35. J.A. Delmez J. Kelber K.Y. Norword K.S. Giles E. Slatopolsky Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study Kidney Int 49 1996 163 167
36. G.M. Chertow S.K. Burke J.M. Lazarus K.H. Stenzel D. Wombolt D. Goldberg J.V. Bonventre E. Slatopolsky Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure J Kidney Dis 29 1997 66 71
37. A.U.J. Tan B.S. Levine R.B. Mazess D.M. Kyllo C.W. Bishop J.C. Knutson K.S. Kleinman J.W. Coburn Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism Kidney Int 51 1997 317 323
38. K.J. Martin E.A. Gonzalez M. Gellens L.L. Hamm H. Abboud J. Lindberg 19-Nor-1-alpha-25-dihyrdoxyvitamin D-2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis J Am Soc Nephrol 9 1998 1427 1432
39. J.E. Antonsen D.J. Sherrard D.L. Andress A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Kidney Int 53 1998 223 227